Cellect Biotechnology Announces Positive Clinical Trial Results
Cellect Biotechnology Ltd. recently announced positive final results from its clinical trial of ApoGraft in healthy donors. The study’s primary objective was to validate the company’s propriety method of stem cell selection by going through the process of production and characterization with ApoGraft, and was conducted on samples obtained in collaboration with two leading medical centers in Israel, The Schneider Children’s Medical Center and the Rambam Medical Center.
Cellect’s technology enables the use of stem cells for regenerative therapies by eliminating mature cells while leaving the stem cells unharmed using a natural process occurring in the human body, apoptosis (programed cell death), which “orders” cells to commit suicide. Cellect’s validated scientific platform, and the focus of its 7 families of patents, is that the apoptosis command destroys primarily mature cells, while stem cells remain alive and flourishing. This process allows for natural enrichment of stem cells, thus enabling stem cell-based therapies or transplantation to possess an abundance of quality stem cells with little to no risk of rejection or other complications, such as Graft versus Host Disease (GvHD).
The study included 104 healthy donors of blood stem cells. The samples (collected under approval of Helsinki committees) represented 5% of a graft used for transplantation into patients. The grafts were processed allowing stem cell production for transplantation with Cellect’s ApoGraft. The use of the ApoGraft resulted in a significant increase in the death of mature immune cells, primarily T Lymphocytes, without compromising the quantity and quality of stem cells. The process takes only a few hours as compared to days of complex and expansive lab work with traditional methods, is anticipated to be extremely cost effective in comparison to current approaches, and has the potential to significantly reduce the risk of GvHD.
“These results from processing human stem cells for bone marrow transplantation using ApoGraft clearly demonstrated that Cellect’s proprietary platform could improve the outcome of stem cell transplantations in patients suffering from hematological malignancies,” said Dr. Yaron Pereg, Cellect’s Chief Development Officer.
Cellect Biotechnology has developed a breakthrough technology for the isolation of stem cells from any given tissue that aims to improve a variety of stem cells applications. The company’s technology is expected to provide pharma companies, medical research centers, and hospitals with the tools to rapidly isolate stem cells for in quantity and quality that will allow stem cell-related treatments and procedures. Cellect’s technology is applicable to a wide variety of stem cell-related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations. For more information, visit www.cellectbio.com.
Total Page Views: 1164
